dissemination – Page 67 – Communicable Diseases Research

Addressing challenges for clinical research responses to emerging epidemics and pandemics: a scoping review

Research Article

Published on 2020-06-252022-10-28
Journal: BMC Medicine [Category] Coronavirus, Fulltext, SARS, 신종인플루엔자,

COVID-19 in Smokeless Tobacco Habitués: Increased Susceptibility and Transmission

Infectious Disease

Published on 2020-06-252022-10-31
Journal: Cureus [Category] COVID-19,

Rapid publications risk the integrity of science in the era of COVID-19

Opinion

Published on 2020-06-252022-10-28
Journal: BMC Medicine [Category] COVID-19, SARS,

Digital Approaches to Remote Pediatric Health Care Delivery During the COVID-19 Pandemic: Existing Evidence and a Call for Further Research

Viewpoint

Published on 2020-06-252022-10-29
Journal: JMIR Pediatrics and Parenting [Category] COVID-19,

[키워드] accountability Act acute illness addressed adolescents affected approach approaches Care change children coronavirus coronavirus disease COVID-19 COVID-19 crisis COVID-19 outbreak COVID-19 pandemic delivery Digital Digital health Digital medicine dissemination effective effort eHealth equity Final Future Health health care delivery Health care system highlight implementation insurance interventions investigator Involving management mental health mHealth Mobile health outbreak overcome pandemic Pandemics Parenting Patient Patient care patients pediatric pediatrics Perspective populations protected health information public health public health threat question rapid expansion remote Research resource Safe SARS-CoV-2 Spread Streamline Support telehealth Telemedicine Variation
[DOI] 10.2196/20049 PMC 바로가기 [Article Type] Viewpoint

Targeting the NLRP3 Inflammasome in Severe COVID-19

Immunology

Published on 2020-06-232022-11-01
Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS,

[키워드] accompanied Activation acute respiratory distress acute respiratory distress syndrome (ARDS) acute respiratory syndrome ARDS cause caused characteristic characterized Complication coronavirus coronavirus disease COVID-19 Cytokine release syndrome (CRS) Cytokine storm dissemination dysregulated family Coronaviridae fatality genus Betacoronavirus hyperinflammation IL-1β IL-1β IL-6 Infection inflammasome pathway Inflammatory cytokine innate immune response Mild NLRP3 NLRP3 inflammasome occur occurred Pathogenesis pathology pathway Proinflammatory cytokine receptor respiratory RNA virus SARS-CoV-2 SARS-COV-2 infection severe cases severe COVID-19 severe disease severe lung injury single-stranded positive-sense syndrome systemic inflammatory targeting tissue Treatment Trigger viral infection viral replication widespread
[DOI] 10.3389/fimmu.2020.01518 PMC 바로가기 [Article Type] Immunology

The mystery of the COVID toes – turning evidence-based medicine on its head

Commentary

Published on 2020-06-232022-10-30
Journal: Journal of Foot and Ankle Research [Category] Coronavirus, SARS,

[키워드] can be used case study children Clinical data COVID COVID-19 COVID-19 infection dissemination Evidence Evidence Based Medicine Healthcare professional Infection information lesions Research the disease
[DOI] 10.1186/s13047-020-00408-w PMC 바로가기 [Article Type] Commentary

Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data

Infectious Diseases

Published on 2020-06-212022-10-28
Journal: BMJ Open [Category] COVID-19, Fulltext, SARS,

[키워드] acute respiratory syndrome adverse events Analysis antimicrobial antimicrobial drug approval association attack rate Characteristics Committee coronavirus COVID-19 COVID-19 epidemic COVID-19 pandemic Cox model dataset death determine dissemination Effectiveness enhanced Epidemiology Ethics evaluate expand healthcare highest hospitalisation individual International Intervention Laboratory laboratory data MONITOR morbidity and mortality Mortality multivariate logistic regression National pandemic peer-reviewed platform Poisson regression models preventive intervention primary care Primary outcome prospective observational cohort protective effect protocol public health Registered required respiratory medicine (see thoracic medicine) risk SARS-CoV-2 SARS-COV-2 infection Scottish secondary outcome service Study design Surveillance therapeutic therapeutic intervention Therapies Vaccine
[DOI] 10.1136/bmjopen-2020-039097 PMC 바로가기 [Article Type] Infectious Diseases

COVID–19-associated coagulopathy: An exploration of mechanisms

Review Article

Published on 2020-06-192022-10-28
Journal: Vascular Medicine (London, England) [Category] COVID-19, MERS, SARS,

[키워드] activated Activation acute respiratory distress anticoagulation antiplatelet characterized Clinical finding clinical trial clotting factors Coagulation Coagulopathy complement component contribute coronavirus disease COVID-19 Critical Critically ill patient D-dimer Degradation disease severity dissemination dysregulation effort Elevation endothelial injury global pandemic Hemostasis hypercoagulable Inflammation Inflammatory cytokines initiated innate immune system International Laboratory limit mechanism mechanisms microparticles Mortality MOST Neutrophil extracellular traps Neutrophils pathophysiology pathway Patient patients with COVID-19 Platelets predictor Respiratory failure resulting SARS-CoV-2 SARS-COV-2 infection syndrome this system thrombin thrombosis Vascular endothelium venous thromboembolism (VTE) viral infection Viral pneumonia virus
[DOI] 10.1177/1358863X20932640 PMC 바로가기 [Article Type] Review Article

Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-192022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 24 hour acute respiratory distress Administered administration Aerogen Aerogen Solo® Aerosols age airway alveolar alveolar injury anticipated ARDS backbone Berlin criteria blinded blocker Breastfeeding carrier cell-free DNA citrullinated histones clearance cleave Clinical practice clinical trial comparator Compound computer-generated consecutive patient control arm coronavirus 2 coronavirus disease COVID-19 COVID-19 patients criteria damage-associated molecular pattern DAMP DAMPs diagnosed with COVID-19 dissemination distal Dornase alfa dose double-stranded DSMB Efficacy element eliminated enteral nutrition Extracellular extracellular DNA fibrosis glycemic control hospital Hospitalized hospitals hyperinflammation hypersensitivity ICU Inclusion inclusion criteria induce Inflammation intensive care interim analysis Intervention Ireland less looser lung lung damage Lungs management mechanical ventilation mechanically ventilated patient monitoring board myeloperoxidase NET NETs neutrophil Neutrophil extracellular trap Neutrophil extracellular traps number objective Occurrence Open-label outcome PaO Paris participant Patient patients PEEP performed Pneumocytes Primary outcome progression Prone position Protective protocol randomisation randomised randomised controlled trial Randomized receive recruit recruitment reduce reducing Registered respiratory Roche Rothschild Sample size SARS-CoV-2 secretion Sedation Severe COVID-19 pneumonia severe pneumonia severity statistical analysis status study group Study protocol Switzerland syndrome to define Toxicity tracheal Treatment Trial usual care Ventilation vibrating mesh nebulizer Volume website
[DOI] 10.1186/s13063-020-04488-8 PMC 바로가기 [Article Type] Letter

AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial

AGILE-ACCORD: COVID-19 치료를 위한 여러 후보 약제의 최적 용량, 안전성 및 효능을 결정하기 위한 무작위, 다기관, 원활한, 적응 I/II상 플랫폼 연구: 무작위 플랫폼에 대한 연구 프로토콜의 구조화된 요약 재판

Letter

Published on 2020-06-192022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] 9-point ordinal scale acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive added Adult patients Adverse adverse events agent Anti-viral treatment approval Bayesian Blinding candidate Candidates clinical Clinical improvement cloud Cohort cohorts Combination Common Terminology Criteria Community community setting comparator contributing to coronavirus COVID-19 COVID-19 infection CST cytokine cytokine release death defined determine disease dissemination dose EDC Efficacy Efficacy and safety element eligibility criteria eligible England EudraCT evaluated expected for inclusion futility GRADE group hospitalised hospitalised patient Hospitalization in some include Infection intubation Ireland laboratory-confirmed later phase limit Mask Master protocol mechanical ventilation mechanism mechanism of action multi-arm multicentre Multiple nasal prongs non-invasive ventilation North number objective open Open-label opens optimal dose Ordinal Scale organ Other outcome oxygen oxygen saturation oxygen) participant Patient patient population patients peripheral capillary Peripheral capillary oxygen saturation phase Phase I/II Placebo platform Platform study Platform trial Population Prevent progression of disease promise protocol randomisation randomised Rave recruited recruitment Regulatory required respiratory Safety Sample size SARS-CoV-2 SARS-COV-2 infection seamless setup severe acute respiratory syndrome Coronavirus severe disease shown SOC Specific Stage Standard Standard of care status Study protocol the WHO toxicities Toxicity Treatment treatment of COVID-19 Trial Trial registration Ventilation Viral Viral load viral replication website WHO working
[DOI] 10.1186/s13063-020-04473-1 PMC 바로가기 [Article Type] Letter